Article · 2015
EditorialPublished 2012
Could Gemcitabine Change the Suffering of Pancreatic Cancer Patients?:-Varidation of this Decade and Expectation of Next Decade
Similar by topic
Other · May 2011
Chronic Pancreatitis and Chronic Pancreatopathy . Physiopathogenic, Clinical and Functional Evaluation - Experience with 1,300 case during three decades.
Conference abstract · 5 Jan 2023
Cancer-associated fibroblasts suppress ferroptosis and induce gemcitabine resistance in pancreatic cancer cells through exosome-derived ACSL4- targeting miRNAs
Conference abstract · 21 Nov 2022
Cancer-associated Fibroblasts suppress ferroptosis and induce gemcitabine resistance in pancreatic cancer cells though exosome derived ACSL4 -targeting miRNAS
Conference abstract · 23 Oct 2019
Targeted Intra-arterial Gemcitabine: Impact on Survival in Patients with Locally Advanced Pancreatic Cancer—A New Treatment Paradigm
More from this journal
The newest in Pancreatic Disorders & Therapy.
Commentary · 27 May 2026
Systemic Inflammatory Spillover in Pancreatic Disease: Multiorgan Impact, Mediator Networks, and Clinical Consequences
Short communication · 27 May 2026
Immunometabolic Interactions in Pancreatic Disease: Crosstalk Between Energy Dysregulation, Immune Activation, and Tissue Dysfunction
Commentary · 27 May 2026
Microvascular Dysfunction in Pancreatic Disorders: Endothelial Injury, Perfusion Failure, and Tissue Consequences
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalPancreatic Disorders & Therapy
- SubjectGastroenterology & Hepatology
- SubjectPathology & Lab Medicine
- BylineArticles whose byline prints “Toru Ishikawa”

